ImmunityBio Sued as FDA Flags Misleading Cancer Drug Efficacy Claims

In a move reflecting heightened regulatory scrutiny in the biotech sector, ImmunityBio is facing a securities class action lawsuit on behalf of investors who acquired securities between January and March 2026. The legal action follows a warning letter from the U.S. Food and Drug Administration (FDA) regarding misleading efficacy claims for its lead biologic product, Anktiva. According to reports, this news caused the company's shares to plunge 21%, wiping out approximately $2 billion in market capitalization.

This crisis hits at a sensitive time for the biotechnology industry, where regulatory pressure has intensified on firms overstating clinical trial results. In comparison to sector peers, companies like Cassava Sciences have previously faced similar pressures that led to sharp market value declines per market data. Legal experts note that the lawsuit filed by Hagens Berman focuses primarily on statements made by the executive chairman that may have violated federal securities laws.

On the technical front, traders are monitoring upcoming support levels following the recent crash, while awaiting any official response from the company that might soothe investor fears. Looking at the economic calendar, the market awaits Fed Governor Waller's speech on May 19, 2026, which could influence risk appetite in the growth and biotech sectors. The company's ability to address the FDA's concerns will remain the primary catalyst for stock stability in the near term.